In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego, California and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

SUNDAY, JANUARY 26

MONDAY, JANUARY 27

TUESDAY, JANUARY 28

WEDNESDAY, JANUARY 29

Sunday, January 26

REGISTRATION

2:30-7 p.m.

WELCOME AND OPENING Keynote

6:15-7 p.m. | CME Eligible

  • Michael Baumann, DFKZ German Cancer Research Center, Heidelberg, Germany 

Opening Reception

7-9 p.m.

Monday, January 27

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 1: FLASH

8-10 a.m. | CME Eligible

Session Chair: Marie-Catherine Vozenin, Lausanne University Hospital, Lausanne, Switzerland 

  • FLASH, an opportunity for the treatment of pediatric brain tumors or Transcriptional imprint of FLASH radiotherapy 
    Marie-Catherine Vozenin, Lausanne University Hospital, Lausanne, Switzerland 
  • Proton FLASH radiotherapy: How lessons from preclinical models inform clinical trials 
    Constantinos Koumenis, University of Pennsylvania, Philadelphia, Pennsylvania
  • Jeffery C. Buchsbaum, National Cancer Institute, Rockville, Maryland

Short talks from highly rated abstracts.

BREAK

10-10:30 a.m.

Spotlight Session Topic to be Announced

11 a.m.-12 p.m.

Lunch on own

12-1:30 p.m.

Plenary Session 2: Nodal management with immune checkpoint therapy 

1:30-3:30 p.m. | CME Eligible

  • To treat or not to treat: Nodal irradiation in the context of immunotherapy
    Sana D. Karam, Washington University School of Medicine, St. Louis, Missouri
  • J. Sylvio Gutkind, University of California, San Diego, San Diego, California 
  • Quynh-Thu Le, Stanford Cancer Institute, Stanford, California

Short talks from highly rated abstracts.

Break

3:30-4 p.m.

Plenary Session 3: Theragnostics and external beam 

4-6 p.m. | CME Eligible

  • Chemical strategies to expand the therapeutic window of targeted radiotherapies
    Michael Evans, University of California San Francisco, San Francisco, California
  • Rebecca K.S. Wong, UHN Princess Margaret Cancer Center, Toronto, ON, Canada
  • Opportunities and approaches for combining theranostics and other forms of radiation therapy for cancer
    Zachary Morris, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Short talks from highly rated abstracts.

Poster Session A and Reception

6-7:30 p.m.

Tuesday, January 28

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 4: AI in radiation therapy

8-10 a.m. | CME Eligible

  • Clinical implementation of AI in radiation therapy
    Steven B. Jiang, UT Southwestern, Dallas, Texas
  • Translating language models into the oncology clinic: Approaches for scalable evaluation and oversight 
    Danielle S. Bitterman, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Ruijiang Li, Stanford University, Stanford, California

BREAK

10-10:30 a.m.

Proffered Talks 

10:30-11:30 a.m. | CME Eligible

In honor of Dr. C. Norman Coleman

Lunch on own

11:30 a.m.-1 p.m.

Plenary Session 5: Ferroptosis and radiation 

1-2:30 p.m. | CME Eligible

  • Targeting ferroptosis in radioresistance 
    Boyi Gan, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Understanding ferroptosis molecular mechanisms to advance ferroptosis therapies in cancer 
    Scott Dixon, Stanford University, Stanford, California
  • Strategies to mitigate the side effects of ferroptosis in tumor treatment
    Daolin Tang, UT Southwestern Medical Center, Dallas, Texas

Break

2:30-2:45 p.m.

Plenary Session 6: Integrating DNA damage repair targeting with radiation therapy

2:45-4:15 p.m. | CME Eligible

  • Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York
  • Meredith A. Morgan, University of Michigan, Ann Arbor, Michigan
  • Vulnerabilities of pathologic DNA damage responses
    Gaorav P. Gupta, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Plenary Session 7: Role of radiation and cell therapy 

4:30-6 p.m. | CME Eligible

  • Low-dose total body irradiation improves response to CAR T cell therapy 
    Monica L. Guzman, Weill Cornell Medical College, New York, New York
  • Radiation of hematological malignancies: insights into sublethal dosing and salvage immune therapies enhancement
    Joachim Yahalom, Memorial Sloan Kettering Cancer Center, New York, New York
  • NK-Cell based CAR Therapy: Current status and future directions
    Hind Rafei, The University of Texas MD Anderson Cancer Center, Houston, Texas

Poster Session B and Reception  

6-7:30 p.m.

Wednesday, January 29

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 8: Update on radiation and immunotherapy

8-10 a.m. | CME Eligible

  • David G. Kirsch, UHN Princess Margaret Cancer Center, Toronto, Canada 
  • Silvia C. Formenti, Weill Cornell Medicine, New York, New York
  • Andy J. Minn, University of Pennsylvania, Philadelphia, Pennsylvania

Short talks from highly rated abstracts

BREAK

10-10:30 a.m.

KEynote

10:30-11:15 a.m.

  • Radiotherapy immunotherapy interactions: Determinants of success and failure 
    Ralph R. Weichselbaum, University of Chicago, Chicago, Illinois

Plenary Session 9: Emerging therapeutics or biomarkers for radiation therapy  

11:15 a.m.-12:45 p.m. | CME Eligible

  • Liquid biopsies for noninvasive detection and characterization of cancers
    Maximillian Diehn, Stanford University, Stanford, California
  • Albert C. Koong, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Therapeutic strategies and biomarker approaches for chromosomal instability
    Samuel F. Bakhoum, Memorial Sloan Kettering Cancer Center, New York, New York

Closing Remarks and Departure

12:45 p.m.